






































Obesity Does Not Affect Early Outcomes in Children
With Newly Diagnosed Crohn Disease
Animesh Jain, yJosh Bricker, zMichael D. Kappelman, and y§Jennifer L. Dotson
ABSTRACT
The impact of obesity on pediatric Crohn disease (CD) remains poorly
characterized. We aimed to evaluate disease-related outcomes in overweight
and obese children with CD, compared to normal-weight children. We
conducted a retrospective cohort study of children with newly diagnosed CD
enrolled in the ImproveCareNow Network. Patients were stratified into
normal weight, overweight, and obese groups using standardized weight
percentiles. A total of 898 children were included, with 87 children (10%)
being overweight and 43 children (5%) being obese; baseline characteristics
were similar between groups. There was no significant difference in number
of visits in remission during 1 year between normal weight, overweight, and
obese children. At 1-year follow-up, nutritional status, growth status, or
medication use also did not differ between groups. Hence, obesity does not
appear to adversely affect CD outcomes in children with newly diagnosed
CD in the first year after diagnosis.
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O besity among children is a growing challenge in the UnitedStates with approximately 15% of children being over-
weight and an additional 17% being obese, defined by age-specific
growth charts (1,2). Although obesity is typically considered a
proinflammatory state, the impact of obesity on immune-mediated
diseases, such as Crohn disease (CD), is not entirely clear (3,4).
Limited data in adult patients show conflicting impact of obesity on
inflammatory bowel disease (IBD), with some studies suggesting
increased disease flares and complications, whereas other studies
show no impact or even reduced need for surgery in obese patients
with IBD (5–9). Literature on obesity in pediatric IBD is even more
limited, with very few reports directly addressing this issue. The
aim of the present study was to use a large multicenter cohort of
children with newly diagnosed CD to evaluate the impact of obese
and overweight status on IBD-related outcomes.
METHODS
Study Design
We performed a retrospective cohort study of children with
newly diagnosed CD enrolled in the ImproveCareNow (ICN)
Network from September 2006 to October 2014. The ICN Network
includes prospectively collected data regarding demographic fac-
tors, IBD phenotype, IBD disease course, treatment course, and
disease-related outcomes. Data are entered into the ICN database by
clinicians or research personnel. For the present analysis, we
included patients with a first visit within 90 days of CD diagnosis
and at least 1 follow-up visit within 12 to 18 months after diagnosis.
All children with age >2 years (24 months) and <21 years (252
months) were included. Patients were excluded if weight, height,
sex, or birthdate were missing at baseline or 1-year follow-up.
Underweight children, as defined by body mass index (BMI)<10th
percentile at baseline or 1-year follow-up, were also excluded.
Exposure Variables (Overweight/Obese Status)
Using BMI at the initial visit, patients were categorized into
obese, overweight, and normal-weight groups. For children ages 2
to 20 years, the Centers for Disease Control and Prevention age- and
sex-specific nomograms were used to categorize patients by weight
status. Obesity was defined as BMI 95th percentile and over-
weight was defined as BMI between 85th and 94th percentile for
given age and sex. Normal weight was defined as 10th to 84th
percentile. For patients ages 20 years, traditional BMI cut points
What Is Known
 The role of obesity in adults with Crohn disease is
unclear, with some reports suggesting worsened
disease course, whereas other reports suggest
no impact.
 Little is known about the role of obesity in children
with Crohn disease.
What Is New
 In this cohort of children with newly diagnosed
Crohn disease, obesity appears to have no impact
on Crohn disease course at 1 year.
 Further study is warranted to evaluate longer-term
impact of obesity in pediatric Crohn disease.
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sedimentation rate and albumin, were, however, similar between
groups (Table 2).
Some children did change weight category from baseline
through the 1 year of follow-up. Among children who were normal
weight at baseline, 66 children increased to overweight (9% of
the normal weight cohort) and 16 children (2%) increased to obese
at 1-year follow-up. Among children who were obese at baseline,
7 children (16%) decreased to overweight and 5 children (12%)
decreased to normal weight. There was more movement in the
group of children who were overweight at baseline. Amongst these
overweight children, 22 children (25%) increased to the obese
category and 28 children (32%) decreased to normal weight.
For most data fields shown in Tables 1 and 2, the proportion
of missing data was small (<10% missing). Notable exceptions
include Paris Classification, in which approximately 45% of chil-
dren had missing data, and sPCDAI, in which 35% of children had
missing data. The proportion of missing data was similar between
normal-weight, overweight, and obese children.
DISCUSSION
Obesity is a growing health challenge in adults and children.
The impact of obesity on CD is poorly characterized, particularly in
children. Our present study looks at children with newly diagnosed
CD and shows no impact of obesity or overweight status on CD
outcomes at 1 year from diagnosis.
Research on the impact of obesity on CD outcomes is limited.
Literature in the adult setting shows conflicting impact of obesity on
IBD course. Early reports seemed to indicate higher rates of
perianal disease, active disease flares, and shorter time to first
surgery amongst obese or overweight adults with CD (5,6). These
studies were, however, somewhat limited by their retrospective
design and relatively small numbers. A more recent retrospective
cohort study of almost 1500 patients showed no association between
BMI and IBD outcomes, including steroid use, anti-TNF use,
hospitalization, or IBD-related surgery (7). A retrospective cohort
by Flores et al (9), included approximately 600 adult patients and
showed lower rates of steroid use, anti-TNF use, hospitalization,
and IBD-related surgery amongst obese adults with IBD. The
authors concluded that obesity may be a marker of less severe
disease.
Literature in the pediatric setting is even more limited. A
2014 study used the Kids’ inpatient database to analyze more than
12,000 hospital admissions of children with IBD and demonstrated
no impact of obesity on rate of perforation, hemorrhage, complex
fistula, or need for surgery (12). This study was, however, limited to
the hospitalized IBD population and focused only on in-hospital
outcomes. In addition, only 1.3% of admissions had a code for
obesity, raising concern for potential undercoding in the dataset. A
2011 study performed a cross-sectional analysis of overweight and
obese children enrolled in ICN. That study showed that prior IBD-
related surgery was associated with overweight or obese status,
suggesting a worsened disease course for these children (13). The
cross-sectional design of that study limited conclusions about
causality and no weight-based differences in other clinical char-
acteristics, including PGA, medication use, or disease phenotype,
were observed.
Although our data show no signs of differing disease course
at 1 year for obese compared with normal-weight children, it is
possible that obesity may have a delayed effect on CD outcomes
that manifests several years later. Moreover, some children with a
normal weight at the time of diagnosis may develop obesity later
in their disease course. Indeed, 11% of children in our cohort
progressed from normal weight at baseline to overweight or obese
at 1-year follow-up. It is unclear whether this subsequent obesity
were used: normal weight BMI 18.5 to 24.9, overweight BMI 25.0 
to 29.9, obese BMI 30.0 (10).
Outcome Variables
The primary outcome was the number of visits in clinical 
remission during 1-year follow-up based on physician global 
assessment (PGA). The visit closest to 1 year from diagnosis 
(and after a minimum of 365 days since diagnosis) was used to 
assess additional secondary outcomes. Secondary outcomes 
assessed include disease activity by short Pediatric Crohn Disease 
Activity Index (sPCDAI), nutritional status (satisfactory, at risk, in 
failure), growth status (satisfactory, at risk, in failure), serologic 
markers of disease (sedimentation rate, hematocrit, albumin), and 
medication treatment differences.
Statistical Analysis
Obese and overweight patients were evaluated as separate 
groups with normal-weight patients as the reference group. The t 
test or nonparametric Kruskal-Wallis rank sum test were used to 
look at differences in continuous variables. Pearson Chi square test 
or Fisher test was used to evaluate bivariate outcomes by weight 
group (obese vs normal; overweight vs normal). Missing data 
variables were omitted from the analysis (pairwise deletion). All 
statistical analyses were performed using R 3.0.1 (11).
The study was approved by the Nationwide Children’s 
Hospital Institutional Review Board.
RESULTS
A total of 898 children with newly diagnosed CD were 
included in the analysis. Table 1 shows demographic and clinical 
characteristics between normal weight, overweight, and obese 
patients at baseline. The majority of children were normal weight  
(n ¼ 768, 85.5%), whereas smaller numbers were overweight 
(n ¼ 87, 9.7%) or obese (n ¼ 43, 4.7%). Children with obesity 
had a younger age at CD diagnosis compared to normal-weight 
children (11.4 vs 12.9 years, P ¼ 0.016). Compared to normal-
weight children, children with obesity also had higher percentage 
of Medicaid insurance (35% vs 12%) and lower percentage of 
commercial insurance (47% vs 74%), P < 0.001. Other demo-
graphic characteristics, including sex and race, were similar 
between groups. CD phenotype and behavior at diagnosis were 
also similar between obese, overweight, and normal-weight 
children.
The primary outcome measure, number of visits in remission 
during 1 year, was similar for children with obesity (3.49 visits) 
compared to normal-weight children (3.98 visits, P ¼ 0.18) and for 
overweight children (3.67 visits) compared to normal-weight chil-
dren (P ¼ 0.16). There was no difference in total number of visits 
between groups or number of visits in steroid-free remission. Other 
secondary outcome measures, including nutritional status, growth 
status, and sPCDAI, were assessed at the visit closest to 1 year. 
There was no difference in these secondary outcomes at 1 year 
(Table 2). Based on sPCDAI, numerically more children with 
obesity had moderate-severe disease compared to normal-weight 
children (20% vs 11%) and fewer children with obesity had inactive 
disease compared to normal-weight children (60% vs 72%). These 
trends were, however, not statistically significant (P ¼ 0.33). Medi-
cation use, including use of steroids, immune suppressants, or 
biologics, was similar between obese, overweight, and normal-
weight children at 1 year. Serum hematocrit was statistically higher 
for children with obesity at 1 year compared with normal-weight 
children (39.5 vs 37.8). Other laboratory measurements, including
studies, obesity status was generally assessed several years into the
patient’s disease course. Because CD can lead to malnutrition and
weight loss, categorizing obesity after several years of disease may
in fact just be a measure of disease severity, as suggested by Flores
et al. There are additional strengths of our study. In particular, the
TABLE 1. Study cohort demographics at baseline visit
Total Normal Overweight P

Obese Py
Total, n 898 768 87 — 43 —
Male, n (%) 558 (62) 477 (62) 50 (57) 0.467 31 (72) 0.248
Age at diagnosis, y, M (SD) 12.8 (3.2) 12.9 (3.1) 12.8 (3.4) 0.636 11.4 (3.9) 0.016
Disease duration (days), Mdn(Q1-Q3) 28 (15–48) 27 (14–48) 37 (22–55) 0.001 31 (16–52) 0.368
BMI, median (IQR) 18.7 (17.0–21.0) 18.3 (16.7–19.9) 23.3 (21–25.6) <0.001 26.8 (22.8–30.4) <0.001
BMI percentile, median (IQR) 50.9 (29.1–73.7) 44.7 (26.7–63.9) 90.0 (87.6–92.4) <0.001 97.7 (96.2–98.4) <0.001
Race 0.064 0.053
White, n (%) 708 (79) 602 (78) 73 (84) 33 (77)
African-American, n (%) 98 (11) 92 (12) 4 (5) 2 (5)
Other,z n (%) 46 (5) 35 (5) 6 (7) 5 (12)
Hispanic, n (%) 24 (3) 13 (2) 6 (7) 0.011 5 (12) 0.005
Insurance 0.461 <0.001
Medicaid, n (%) 121 (13) 93 (12) 13 (15) 15 (35)
Commercial, n (%) 647 (72) 568 (74) 59 (68) 20 (47)
Paris classification
L1: distal 1/2 ileum limited cecal 59 (7) 49 (6) 7 (8) 0.107 3 (7) 0.913
L2: colonic 53 (6) 42 (5) 9 (10) 2 (5)
L3: ileocolonic 199 (22) 176 (23) 15 (17) 8 (19)
L4a: upper disease proximal to
the ligament of Treitz
128 (14) 111 (14) 11 (13) 0.578 6 (14) 0.894
L4b: upper disease distal to
the ligament of Treitz
22 (2) 21 (3) 0 (0) 0.141 1 (2) 1.000
L4a and 4b 37 (4) 35 (5) 1 (1) 0.141 1 (2) 0.697
Behavior
B1: nonstricturing, nonpenetrating 772 (86) 659 (86) 76 (87) 0.652 37 (86) 1.000
B2: stricturing 36 (4) 32 (4) 2 (2) 0.566 2 (5) 0.704
B3: penetrating 46 (5) 38 (5) 5 (6) 0.937 3 (7) 0.479
B2B3: penetrating and stricturing 9 (1) 9 (1) 0 (0) 0.610 0 (0) 1.000
Perianal 166 (18) 140 (18) 18 (21) 0.586 8 (19) 1.000
Nutritional status
Satisfactory 733 (82) 613 (80) 82 (94) 38 (88)
At risk 101 (11) 95 (12) 2 (2) 4 (9)
In failure 18 (2) 18 (2) 0 (0) 0.002 0 (0) 0.669
Growth status
Satisfactory 731 (81) 615 (80) 78 (90) 0.135 38 (88) 0.773
At risk 88 (10) 81 (11) 4 (5) 3 (7)
In failure 35 (4) 32 (4) 2 (2) 1 (2)
PGA§
In remission 322 (36) 275 (36) 34 (39) 0.644 13 (30) 0.691
Mild 357 (40) 308 (40) 30 (34) 19 (44)
Moderate-severe 180 (20) 152 (20) 18 (21) 10 (23)
sPCDAI
Inactive 317 (35) 271 (35) 36 (41) 0.115 10 (23) 0.081
Mild 151 (17) 130 (17) 13 (15) 8 (19)
Moderate-severe 114 (13) 99 (13) 5 (6) 10 (23)
Serologic markers
Sedimentation rate, mean (SD) 22.8 (18.3) 22.6 (18.1) 22.7 (16.8) 0.792 26.3 (23.6) 0.720
Hematocrit, mean (SD) 36.4 (4.5) 36.4 (4.2) 37.1 (5.6) 0.021 36.1 (7.7) 0.756
Albumin, mean (SD) 3.9 (0.6) 3.9 (0.6) 4 (0.6) 0.038 4 (0.5) 0.133
Column percentages are presented by BMI percentile group. Bolded P values represent significant findings.
M ¼ mean; Mdn ¼ median; Q1 ¼ first quartile; Q3 ¼ third quartile; SD ¼ standard deviation; sPCDAI ¼ short Pediatric Crohn Disease Activity Index.
Comparison is between normal and overweight groups.
yComparison is between normal and obese groups.
zOther includes race categories <5% (American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, other, and multiracial).
§Remission status according to physician global assessment (PGA).
would have an impact on CD course, and this would be an 
interesting area to investigate in future studies.
A key difference between our study and prior pediatric and 
adult studies was our use of an inception cohort including assess-
ment of baseline weight status within 90 days of diagnosis. In prior
ICN Network is a large, multicenter cohort with robust data on
clinical measures, disease activity indices, medication data, and
laboratory data. Secondly, we were able to simulate an inception
cohort by including only children with newly diagnosed CD.
Nonetheless, there are some key limitations. Our study only
captures height/weight data within 90 days of diagnosis. Hence, the
characterization of weight status could be affected by weight loss
before diagnosis (resulting in potential bias toward worse outcomes
for normal-weight children). Conversely, weight status could be
affected by steroid use at the time of diagnosis which could bias
toward worse outcomes for overweight or obese children. Also, for
some data fields, most notably the sPCDAI, there was substantial
proportion of missing data (35% missing for sPCDAI). The
proportion of missing data was, however, similar across normal
weight, overweight, and obese children suggesting that missing data
may have been random rather related to obesity status.
In conclusion, this multicenter cohort study shows no impact
of obesity or overweight status on CD outcomes at 1 year after
diagnosis, as measured by multiple clinical endpoints. Longer-term
studies would be beneficial to see whether obesity has an impact on
CD outcomes later in the disease course.
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TABLE 2. Crohn disease outcomes at 1-year follow-up
1 Year follow-up

Normal Overweight P Obese P
Visits, M (SD) 6.98 (2.91) 7.08 (2.82) 0.62 7.30 (2.44) 0.21
Visits in remission by PGA, M (SD) 3.98 (2.18) 3.67 (2.47) 0.16 3.49 (1.67) 0.18
Visits in steroid-free remission, M (SD) 3.15 (1.88) 3.10 (2.12) 0.58 2.81 (1.62) 0.28
BMI, median (IQR) 19.6 (17.6–21.7) 24.8 (21.5–27.2) <0.001 27.5 (21.8–33.7) <0.001
BMI percentile, median (IQR) 54.0 (33.0–73.2) 90.7 (82.0–95.0) <0.001 96.8 (92.5–99.0) <0.001
Nutritional status
Satisfactory 662 (88) 83 (97) 0.066 37 (90) 1.000
At risk 71 (9) 3 (3) 4 (10)
In failure 17 (2) 0 (0) 0 (0)
Growth status
Satisfactory 642 (90) 74 (95) 0.377 40 (98) 0.239
At risk 47 (7) 4 (5) 0 (0)
In failure 21 (3) 0 (0) 1 (2)
PGA
In remission 556 (74) 53 (62) 0.070 32 (74) 0.646
Mild 148 (20) 25 (29) 7 (16)
Moderate-severe 48 (6) 7 (8) 4 (9)
sPCDAI
Inactive 374 (72) 38 (62) 0.254 15 (60) 0.333
Mild 84 (16) 13 (21) 5 (20)
Moderate-severe 59 (11) 10 (16) 5 (20)
Serologic Markers
Sedimentation rate, mean (SD) 15.9 (14.2) 19.3 (15.1) 0.079 14.9 (14.1) 0.637
Hematocrit, mean (SD) 37.8 (3.8) 38.3 (3.0) 0.218 39.5 (5.0) 0.021
Albumin, mean (SD) 4.2 (0.5) 4.2 (0.5) 0.389 4.3 (0.3) 0.420
1-Year follow-up refers to visit closest to 365 days from diagnosis for each variable (within the bounds of 365 and 547 days).
BMI ¼ body mass index; IQR ¼ interquartile range; SD ¼ standard deviation; sPCDAI ¼ short Pediatric Crohn Disease Activity Index.
